Cite
MLA Citation
Frank Stephen Hodi et al.. “Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.” Lancet oncology, vol. 19, no. 11, 2018, pp. 1480–1492. http://access.bl.uk/ark:/81055/vdc_100071726552.0x00001c